ArticleNature communications2020
TIGIT limits immune pathology during viral infections.
Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 75 citations in OpenAlex.
- Spatiotemporal single-cell profiling reveals T cell clonal dynamics and phenotypic plasticity in human graft-versus-host disease.Nature immunology · 2026Article
- Killer-cell immunoglobulin-like receptors define a potent effector program in human γδ T cells.JCI insight · 2026Article
- Immune checkpoint landscape in CD4⁺ T cells stratifies HIV-infected individuals by clinical progression.Immunologic research · 2026Article
- TIGIT agonism as a therapeutic strategy to suppress inflammation in hidradenitis suppurativa.Frontiers in immunology · 2026Article
- From chaos to control: Nobel insights in regulatory T cells and immune tolerance.Pflugers Archiv : European journal of physiology · 2025Review
- A co-stimulatory signal via the coinhibitory TIGIT.Nature immunology · 2025Article
- The co-inhibitory receptor TIGIT promotes tissue-protective functions in T cells.Nature immunology · 2025Article
- Mechanisms of Interleukin-10-Mediated Immunosuppression in Viral Infections.Pathogens (Basel, Switzerland) · 2025Review
- TIGIT antibody with PVR competitive ability enhances cancer immunotherapy and capable of eliciting anti-tumour immune memory.British journal of cancer · 2025Article
- Distinct Immunological Landscapes of HCMV-Specific T Cells in Bone Marrow and Peripheral Blood.Pathogens (Basel, Switzerland) · 2025Article
- TIGIT blockade improves anti-Mycobacterium tuberculosis immunity.PLoS pathogens · 2025Article
- Effector CD8 T cell differentiation in primary and breakthrough SARS-CoV-2 infection in mice.Communications biology · 2025Article
- Prothrombin prevents fatal T cell-dependent anemia during chronic virus infection of mice.JCI insight · 2025Article
- Article
- Emerging IO checkpoints in gastrointestinal oncology.Frontiers in immunology · 2025Review
- CD39 dynamics in tuberculosis: a potential biomarker of immune dysregulation and T cell exhaustion.Frontiers in immunology · 2025Article
- T-cell exhaustion in COVID-19: what do we know?Frontiers in immunology · 2025Review
- Emerging druggable targets for immune checkpoint modulation in cancer immunotherapy: the iceberg lies beneath the surface.Apoptosis : an international journal on programmed cell death · 2024Review
- Synergistic blockade of TIGIT and PD-L1 increases type-1 inflammation and improves parasite control during murine blood-stageInfection and immunity · 2024Article
- Enhancing immunity againstmBio · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Co-inhibitory pathways have a fundamental function in regulating T cell responses and control the balance between promoting efficient effector functions and restricting immune pathology. The TIGIT pathway has been implicated in promoting T cell dysfunction in chronic viral infection. Importantly, TIGIT signaling is functionally linked to IL-10 expression, which has an effect on both virus control and maintenance of tissue homeostasis. However, whether TIGIT has a function in viral persistence or limiting tissue pathology is unclear. Here we report that TIGIT modulation effectively alters the phenotype and cytokine profile of T cells during influenza and chronic LCMV infection, but does not affect virus control in vivo. Instead, TIGIT has an important effect in limiting immune pathology in peripheral organs by inducing IL-10. Our data therefore identify a function of TIGIT in limiting immune pathology that is independent of viral clearance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.